Products

Heuron ICH
Heuron Co.
Neurology AI
Heuron ICH is an FDA-cleared AI software that automatically screens and signals potential intracranial hemorrhage on non-contrast CT images, aiding in rapid triage and improved stroke care.
Veuron-Brain-pAb3
Heuron Co.
Neurology AI
Veuron-Brain-pAb3 by Heuron Co. is an FDA-cleared AI-powered medical imaging software that aids clinicians in the assessment and quantification of amyloid protein concentration from PET and MRI brain scans, supporting the diagnosis of dementia.

See all 2 products →

About Heuron

Heuron is a South Korean medical AI software company specializing in the diagnosis and management of central nervous system (CNS) disorders. The company develops AI-powered solutions designed to perform quantitative analyses on various medical imaging modalities, including MRI, PET, and CT scans. These advanced algorithms are built to integrate the diagnostic insights of clinical specialists, thereby enhancing the accuracy and efficiency of medical image interpretation for complex neurological conditions.

Heuron’s product portfolio addresses critical needs in neurodegenerative diseases and acute neurological emergencies. For neurodegenerative conditions, their solutions, such as Heuron AgingCare Suite™, Heuron IPD, and Heuron Brain PET/AD, facilitate the early and precise diagnosis of Alzheimer’s disease, Parkinson’s disease, and other dementias by identifying subtle changes and providing volumetric analyses of brain regions. In the realm of acute stroke care, Heuron StroCare Suite™, including Heuron ICH for intracranial hemorrhage and Heuron ELVO for emergent large vessel occlusions, offers rapid, non-contrast CT-based diagnostic support, aiming to expedite triage and treatment decisions. These FDA-cleared and CE-certified solutions are intended to reduce clinician workload, improve diagnostic performance, and ultimately contribute to better patient outcomes and potentially accelerate new drug development for CNS disorders.

Focus Areas

Neurodegenerative diseases Stroke Brain metastasis Central nervous system disorders Medical image analysis AI-driven diagnostics

Business Intelligence

Key InvestorsMedTech Innovator, Positive Investment, SBVA, Y&Archer, CNT Tech
PartnershipsMass General Brigham, Thammasat University Hospital, Dr. Park CDMO, Raffles Hospital, Medhealth Informatics (Thailand), Siriraj Hospital (Mahidol University, Thailand), BDMS (Thailand)
TechnologyAI-driven medical image analysis, CT perfusion (CTP) analysis, CT angiography (CTA) analysis, automated ASPECTS-style scoring, neurodegenerative disease detection algorithms, cloud hosting and system management (third-party cloud), web analytics, data encryption and access control, intrusion prevention and audit logging, web-based forms and consent management
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Neurodegenerative Diseases
Heuron offers AI solutions for early detection, quantification, and monitoring of neurodegenerative disorders like Parkinson's disease (Heuron IPD, Heuron NI) and Alzheimer's disease (Heuron AD). Their Parkinson's solutions are the world's first MRI-based AI tools for this purpose, providing a radiation-free alternative to PET scans.
Stroke
The Heuron StroCare Suiteu2122 provides rapid, AI-driven triage and analysis for acute stroke patients. Solutions like Heuron ICH (intracerebral hemorrhage) and Heuron ELVO (large vessel occlusion) identify urgent cases within minutes using non-contrast CT images, with high sensitivity and specificity. Heuron ASPECTS calculates the Alberta Stroke Program Early CT Score.
Brain Metastasis
Heuron METS is an MRI-based AI solution designed for the detection, quantification, and localization of suspected multiple lesions in the brain, providing total and individual lesion volumes along with Talairach coordinates to support treatment decisions.
Central Nervous System Disorders
Heuron specializes in providing diagnosis aid solutions for a range of central nervous system (CNS) diseases, including Parkinson's disease, Alzheimer's disease, stroke, and brain metastasis, by integrating clinical specialists' diagnostic insights into their AI models.
Medical Image Analysis
At its core, Heuron leverages advanced AI for automated analysis of various medical images, including MRI, PET, and CT scans. Their software performs tasks like automatic co-registration, 105 brain region segmentation, volumetric quantification, and partial volume correction.
AI-Driven Diagnostics
Heuron's entire product portfolio is built on AI models, aiming for faster, more accurate, and objective diagnoses. Their AI solutions have demonstrated high sensitivity and specificity in clinical evaluations, enhancing diagnostic workflow and reducing processing times.
Physician Tip

Heuron's AI solutions are designed to significantly enhance clinical workflows and decision-making. Physicians can expect **faster triage and treatment initiation** for acute conditions like stroke, with critical event notifications delivered in real-time to mobile devices. The AI provides **enhanced diagnostic accuracy** for subtle lesions and objective, quantitative measurements for neurodegenerative diseases, potentially reducing diagnostic ambiguity. For Parkinson's disease, the MRI-based AI offers a **non-invasive, radiation-free alternative** to traditional methods. The **automation of image analysis** can lead to reduced workload and improved reading efficiency, allowing physicians to focus more on patient care. Comprehensive, visualized reports also facilitate **better patient communication and longitudinal monitoring** of disease progression.

Heuron's solutions are designed for seamless integration into existing clinical environments. They allow medical professionals to easily verify results through **PACS (Picture Archiving and Communication System)**. Additionally, critical alerts and analysis results can be delivered via **real-time notifications to mobile devices**, enabling prompt action and effective communication across multidisciplinary teams.

Products by Heuron

2 products in the directory

Heuron ICH
Heuron Co.
Neurology AI
Heuron ICH is an FDA-cleared AI software that automatically screens and signals potential intracranial hemorrhage on non-contrast CT images, aiding in rapid triage and improved stroke care.
Veuron-Brain-pAb3
Heuron Co.
Neurology AI
Veuron-Brain-pAb3 by Heuron Co. is an FDA-cleared AI-powered medical imaging software that aids clinicians in the assessment and quantification of amyloid protein concentration from PET and MRI brain scans, supporting the diagnosis of dementia.

Reviews & Opinions

No web reviews on file yet for Heuron. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Heuron.

Loading videos...

Videos load interactively. If none appear, search YouTube for Heuron →

View all on YouTube

Press & Coverage

Heuron
HEURON Global Signs MOU with Thammasat University Hospital to Validate AI Stroke Solution
Heuron Global signed an MOU with Thammasat University Hospital in Thailand to validate its AI stroke solution, aiming to expand its presence in the global healthcare market. This collaboration focuses on clinical research and validation of Heuron's AI technology for stroke analysis.
2026-02
Heuron
Heuron Collaborates on Clinical Research for Parkinson's Disease Gene Therapy
Heuron is collaborating on clinical research for Parkinson's Disease gene therapy, indicating its commitment to advancing treatments for neurodegenerative diseases through innovative approaches. This initiative highlights the company's focus on cutting-edge research in the field.
2026-01
Heuron
Heuron Demonstrates Economic Value of AI-Based Parkinson's Disease Triage Technology in International Journal
Heuron published findings in an international journal demonstrating the economic value of its AI-based Parkinson's Disease triage technology, underscoring the practical benefits and cost-effectiveness of its diagnostic solutions. This publication validates the impact of their AI technology in a clinical setting.
2025-12
Heuron
Heuron Secures PMDA Approval for Stroke Analysis Solution, Accelerates Entry into Japanese Market
Heuron received PMDA (Pharmaceuticals and Medical Devices Agency) approval for its stroke analysis solution, facilitating its accelerated entry into the Japanese market. This regulatory milestone is crucial for expanding the availability of their AI-powered diagnostic tools in Japan.
2025-11
Heuron
Heuron Hosts Delegation from Uzbekistan Ministry of Health for Discussions on Stroke AI Adoption
Heuron hosted a delegation from the Uzbekistan Ministry of Health to discuss the adoption of its Stroke AI solutions, indicating international interest in their technology for improving stroke care. This engagement suggests potential for global partnerships and market expansion.
2025-08
Heuron
Heuron Acquires 2 Additional Taiwan FDAs 'Accelerating Entry into Taiwan'
Heuron has acquired two additional Taiwan FDA approvals, further accelerating its entry into the Taiwanese market with its medical AI solutions. This expands their regulatory clearances and market reach in Asia.
2025-07
Heuron
Heuron, appoints two world-renowned stroke experts to medical advisory board
Heuron has appointed two world-renowned stroke experts to its medical advisory board, strengthening its expertise and guidance in the development and application of stroke-related AI solutions. This enhances the credibility and scientific rigor of their products.
2025-06
ImagineHealth
ImagineHealth Announces Strategic Collaboration with Neurolink AI and Heuron Global
ImagineHealth announced a strategic collaboration with Neurolink AI and Heuron Global to introduce advanced brain health diagnostics, specifically Heuron's AI-powered neuroimaging solutions, to hospitals and clinics in Thailand. This partnership aims to enhance preventive and longevity care by quantifying brain age and detecting early indicators of neurodegenerative diseases.
2026-05

Frequently Asked Questions

Heuron provides AI-driven diagnostic solutions for central nervous system disorders, including neurodegenerative diseases like Parkinson's (Heuron IPD, Heuron NI, Heuron NM) and Alzheimer's (Heuron AD, Veuron-Brain-pAb3), as well as comprehensive stroke solutions (Heuron StroCare Suite, Heuron ICH, Heuron ELVO, Heuron CTP, Heuron CTA, Heuron ASPECTS) and Heuron METS for brain metastasis. These solutions primarily leverage MRI and CT imaging modalities for analysis.
Heuron's AI solutions have undergone clinical validation, including trials with institutions like Mass General Brigham, affiliated with Harvard Medical School. For instance, Heuron ICH for intracranial hemorrhage boasts 86% sensitivity and 88% specificity, while Heuron IPD for Parkinson's disease shows a sensitivity of 97%, specificity of 95.7%, and accuracy of 96.6% in identifying patients.
Heuron holds significant regulatory clearances, including five FDA 510(k) clearances for solutions like Heuron ICH and Veuron-Brain-pAb3. The company also possesses 15 domestic medical device approvals/certifications, four European CE (MDD) certifications, and various other international certifications. Additionally, Heuron is certified for GDPR, HIPAA, and CSA-STAR, demonstrating a commitment to data privacy and security.
Heuron prioritizes data security and privacy, holding certifications such as GDPR, HIPAA, and CSA-STAR. The company implements security programs to prevent personal information leakage, conducts regular updates and inspections, and stores personal information in controlled physical locations with access control procedures. User personal information is encrypted and managed securely.
Heuron's AI solutions are designed to integrate as diagnosis aid tools, enhancing workflow and diagnostic accuracy by providing rapid and accurate analysis of medical images. While specific integration methods (e.g., PACS, EHR) are typically detailed during implementation, Heuron aims to minimize the gap between AI technology and end-users' needs. Details regarding specific technical support channels and service level agreements are generally established through direct engagement with the company.
Heuron has established numerous strategic partnerships with leading medical institutions, including Ajou University Hospital, Gangnam Severance Hospital, Seoul St. Mary's Hospital, and Mass General Brigham. The company is actively expanding its global market presence through distribution agreements in Thailand and Taiwan, an exclusive distribution agreement in Japan, and supply contracts in Singapore. They also have MOUs with Siemens Healthineers and University Hospital Gu00f6ttingen, Germany.
Heuron is a Series B company that has raised over $15 million in funding and is currently in the 'Generating Revenue' stage. Led by a neurologist CEO, their long-term vision is to continue developing innovative AI solutions for early brain disease diagnosis and treatment, aiming to reduce drug development time and cost while increasing clinical trial success rates for CNS disorders. The company maintains a robust R&D pipeline with over 20 clinical data-centered diagnostic programs.

Investors

Who's funded Heuron.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.